These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
693 related articles for article (PubMed ID: 35663947)
1. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL. Jeyakumar N; Smith M Front Immunol; 2022; 13():887866. PubMed ID: 35663947 [TBL] [Abstract][Full Text] [Related]
2. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Doraiswamy A; Shah MR; Bannerji R Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745 [TBL] [Abstract][Full Text] [Related]
5. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325 [TBL] [Abstract][Full Text] [Related]
6. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W Front Immunol; 2021; 12():755549. PubMed ID: 34777367 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440 [TBL] [Abstract][Full Text] [Related]
8. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407 [TBL] [Abstract][Full Text] [Related]
9. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489 [TBL] [Abstract][Full Text] [Related]
10. Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car. Scordo M; Lin RJ; Sauter CS Curr Opin Hematol; 2019 Jul; 26(4):288-293. PubMed ID: 31170111 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL. Del Bufalo F; Becilli M; Rosignoli C; De Angelis B; Algeri M; Hanssens L; Gunetti M; Iacovelli S; Li Pira G; Girolami E; Leone G; Lazzaro S; Bertaina V; Sinibaldi M; Di Cecca S; Iaffaldano L; Künkele A; Boccieri E; Del Baldo G; Pagliara D; Merli P; Carta R; Quintarelli C; Locatelli F Blood; 2023 Jul; 142(2):146-157. PubMed ID: 37172203 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. Cao XY; Li JJ; Lu PH; Liu KY Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192 [TBL] [Abstract][Full Text] [Related]
13. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma. Duarte C; Kamdar M Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892 [TBL] [Abstract][Full Text] [Related]
15. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Albanyan O; Chavez J; Munoz J Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy. Hilal T; Mountjoy LJ Curr Oncol Rep; 2023 Jun; 25(6):599-607. PubMed ID: 36976461 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703 [TBL] [Abstract][Full Text] [Related]
18. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature. Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H Front Immunol; 2022; 13():1063986. PubMed ID: 36713414 [TBL] [Abstract][Full Text] [Related]
19. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer? Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495 [TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Trabolsi A; Arumov A; Schatz JH Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]